Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | Phase I trial of NTX1088, a novel anti-PVR mAb, in solid tumors

Pini Tsukerman • 27 Apr 2023
AACR 2023
General Antibodies NTX1088

Pini Tsukerman, PhD, Nectin Therapeutics, Jerusalem, Israel, provides an overview of the Phase I trial (NCT05378425) of NTX1088, a first-in-class anti-PVR monoclonal antibody, in patients with solid tumors. The novel antibody targets three major receptors, TIGIT, CD96 and KIR2DL5A, and a first-in-human trial is currently underway to assess safety and pharmacodynamics. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Pini Tsukerman

3:01
The development of anti-nectin monoclonal antibodies
Pini Tsukerman • 27 Apr 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals